STOCK TITAN

GLAUKOS (GKOS) SEC Filings, Oct-Nov 2026

GKOS NYSE

Glaukos Corporation filings document the regulatory record for an ophthalmic pharmaceutical and medical technology company with common stock listed on the New York Stock Exchange under GKOS. Recent Form 8-K reports furnish quarterly and annual financial results, preliminary net sales information, supplemental business summaries, and Regulation FD investor presentations.

The company’s proxy materials provide governance and executive-compensation disclosures, including equity-award and pay-versus-performance information. These filings also identify Glaukos as a Delaware corporation and frame disclosure around its glaucoma, corneal-disorder, and retinal-disease therapies, commercial products, risk disclosures, and public-company reporting obligations.

Rhea-AI Summary

Glaukos Corp. (GKOS) officer Joseph Gilliam reported a proposed sale of 44,917 common shares, with an approximate sale date of November 12, 2026. The notice lists an aggregate market value of $11,063,735.46 and 59,196,870 shares outstanding. It lists August 13, 2026 as the plan adoption or instruction date for reliance on Rule 10b5-1.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.13%
Tags
other
-
Rhea-AI Summary

Glaukos Corporation’s November 2026 investor presentation outlines 14 disclosed pipeline programs and 12 currently commercialized products. It reports 30% topline growth in 2025, a 20% 10-year revenue CAGR, and $900 million invested in research and development since 2018.

The presentation says iDose TR is FDA-approved for re-administration (January 2026); 81% of subjects were free of IOP-lowering topical medications at 12 months, while 70% were well-controlled on the same or fewer medications at three years. Epioxa became commercially available in March 2026. As of September 30, 2026, Glaukos reported $340 million in cash and equivalents and no debt; 3Q 2026 gross margin was 88%, adjusted for certain accounting and other adjustments.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.01%
Tags
current report
-
Rhea-AI Summary

GLAUKOS Corp (GKOS) director Gilbert H. Kliman exercised options for 2,500 shares on November 4, 2026, at $25.77 per share, then sold 2,500 shares at $253 per share that day. The filing reports 10,000 options remaining after the exercise, expiring December 13, 2027. No Rule 10b5-1 plan is reported. A footnote notes 2,501 restricted stock units that had not vested or been delivered, plus vested units whose delivery Kliman deferred.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.01%
Tags
insider
Rhea-AI Summary

GLAUKOS Corp (GKOS) lists Director Gilbert H. Kliman’s proposed sale of 2,500 common shares, with an aggregate market value of $632,500. Fidelity Brokerage Services LLC is listed as broker, and November 4, 2026, as the approximate sale date. The shares are identified as acquired from the issuer through a stock option exercise, with compensation listed. During the prior three months, Gilbert H. Kliman sold 2,500 common shares for $475,000 on August 19, 2026.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.86%
Tags
other
-
Rhea-AI Summary

GLAUKOS Corp director Aimee S. Weisner reported a gift transfer of 2,382 shares of Common Stock on October 30, 2026, from her direct ownership to the Saeman-Weisner Family Trust. After the transfer, she reported 15,801 shares held directly and 31,887 shares through that trust. She also reported 2,000 shares through the Weisner Saeman Family Irrevocable Trust.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.86%
Tags
insider
-
Rhea-AI Summary

GLAUKOS Corp (GKOS) Chief Development Officer Tomas Navratil exercised options on October 30, 2026, acquiring 4,181 shares at $55 per share and 8,788 shares at $85.94 per share. On the same date, he sold 44,436 shares across four reported transactions at weighted-average prices of $237.54, $238.56, $239.64 and $240.52 per share. The corresponding trade-price ranges were $237.09–$238.07, $238.11–$239.11, $239.13–$240.03 and $240.17–$240.87. No Rule 10b5-1 plan is reported.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.86%
Tags
insider
Rhea-AI Summary

GLAUKOS Corp (GKOS) chief development officer Tomas Navratil had 755 common shares withheld by the issuer on April 9, 2024, to satisfy tax withholding obligations upon vesting and delivery of shares underlying restricted stock units. The transactions comprised 495 shares at $87.61 per share tied to units granted March 18, 2021, and 260 shares at $93.23 per share tied to units granted March 24, 2022.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.86%
Tags
insider
-
Rhea-AI Summary

GLAUKOS Corp (GKOS) officer Tomas Navratil reported a proposed sale of 44,436 common shares, with an aggregate market value of $10,618,941.75. The notice lists Fidelity Brokerage Services LLC as broker and October 30, 2026, as the approximate sale date. It also lists four sales during the preceding three months: 13,744 shares on August 28, 2026, for $2,483,097.96; 1,457 shares on September 16, 2026, for $243,207.31; 1,615 shares on September 25, 2026, for $249,157.98; and 1,527 shares on October 5, 2026, for $251,121.33.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.01%
Tags
other
-
Rhea-AI Summary

Glaukos Corporation (GKOS) reported third-quarter 2026 net sales of $211.0 million, versus $133.5 million a year earlier, and net income of $2.0 million versus a $16.2 million loss. Nine-month sales were $547.2 million versus $364.3 million; net loss was $36.1 million versus $54.0 million, while operating cash flow was $40.9 million versus $21.6 million used.

Glaukos completed the transition of commercial efforts and manufacturing from Photrexa to Epioxa in the third quarter; Epioxa’s permanent J-code became effective July 1, 2026. Under a September 29, 2026 agreement with the Regents of the University of California, Glaukos agreed to pay $14.1 million in exchange for release of claims relating to specified patents and a December 2014 agreement; payment occurred in October 2026.

After quarter-end, Glaukos paid $10.0 million upfront for an exclusive RevOpsis license covering one multi-specific biologic and rights to license up to four additional retinal products. Potential milestone payments total up to $875.0 million if all five products are licensed, developed and commercialized; tiered royalties range from 3% to 8% of annual net sales. It also entered a development and lease agreement for a Huntsville facility, with approximately $42.0 million in expected multi-year project costs, and agreed to acquire an Aliso Viejo building for $15.2 million. The building agreement remains subject to closing conditions and is not expected to close until mid- to late-2027.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
33.65%
Tags
quarterly report
Rhea-AI Summary

Glaukos Corporation reported third-quarter 2026 net sales of $211.0 million, up 58% year over year on reported and constant currency bases. GAAP net income was $2.018 million, compared with a $16.231 million loss in Q3 2025; non-GAAP net income was $28.5 million, and non-GAAP diluted EPS was $0.47. GAAP gross margin was 85.2%, versus 78.4%; non-GAAP gross margin was 87.7%, versus 83.9%.

U.S. Glaucoma sales were $118.6 million, up 47% year over year, including approximately $76 million from iDose TR. Corneal Health sales were $59.0 million, up 154%, including approximately $53 million from Epioxa. SG&A expenses were $130.9 million, up 58% year over year, and R&D expenses were $48.1 million, up 26%. Cash, cash equivalents, short-term investments and restricted cash totaled $339.8 million at September 30, 2026; Glaukos reported no debt.

Glaukos raised 2026 net sales guidance to $775 million to $785 million from $680 million to $700 million, based on the latest foreign currency exchange rates. It introduced preliminary 2027 net sales guidance of $1 billion, also based on the latest foreign currency exchange rates.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
33.65%
Tags
current report

FAQ

How many GLAUKOS (GKOS) SEC filings are available on StockTitan?

StockTitan tracks 174 SEC filings for GLAUKOS (GKOS), including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and Form 4 insider trading disclosures. Each filing includes AI-generated summaries, impact scoring, and sentiment analysis.

When was the most recent SEC filing for GLAUKOS (GKOS)?

The most recent SEC filing for GLAUKOS (GKOS) was filed on November 20, 2026.